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ABSTRACT
The incidence of renal cell carcinoma (RCC) is high, and its outcomes
remain poor. Mortality is attributable largely to metastatic disease and a
dearth of effective therapeutic interventions. The lungs are the most
common metastatic site. To elucidate the biological mechanisms
underlying pulmonary metastasis and identify superior therapeutic
strategies, we developed a novel and clinically relevant murine RCC
model exhibiting enhanced pulmonary metastasis. Mice underwent
intrarenal implantation using luciferase-expressing Renca, a murine
renal adenocarcinoma cell line. Primary renal tumor progression
and development of metastatic lung lesions were monitored in live mice
using bioluminescent imaging, followed by post-mortem organ
assessment. Cells were isolated from pulmonary metastases for
reimplantation, followed by repeat monitoring and assessment. This
process was repeated once more for a total of two in vivo passages to
select for pulmonary metastatic Renca cell subpopulations. However, a
single roundof in vivoselectionwassufficient toproduceanear-maximally
metastatic subpopulation. Relative to Renca cell-implanted mice,
subpopulation-implanted mice exhibited shorter implantation-metastasis
intervals (5 days), shorter implantation-moribundity intervals (sacrificed at
18.6±2.9 versus 22.3±1.1 days), a higher number of metastatic lung
lesions at 23 days (183.9±39.0 versus 172.6±38.2) and poorer survival.
Implantation of cells derived from the second round of in vivo selection
produced no further significant differences in the above metrics. This
model consistently and efficiently recapitulates RCC pulmonary
metastasis while allowing in vivo monitoring of tumor progression,
thereby facilitating elucidation of the molecular mechanisms underlying
pulmonary metastasis and evaluation of therapeutic modalities.
KEY WORDS: Renal cell carcinoma, Metastasis, Kidney, Orthotopic,
Lung, Mouse
INTRODUCTION
Renal cell carcinoma (RCC) is one of the top ten most frequently
diagnosed cancers, with a global incidence of approximately
400,000 cases (Siegel et al., 2019). At the time of initial diagnosis,
almost 30% of patients present with metastatic RCC (mRCC),
whereas approximately 30% of patients presenting with localized
RCC experience recurrence after treatment (Czarnecka et al., 2014).
The most common sites of RCC metastases are the lungs, bone,
liver, and brain (Zekri et al., 2001). Despite significant
improvements in the treatment of advanced RCC over the past 30
years, including targeted therapies and immunotherapies, RCC-
related mortality continues to increase, attributable largely to
metastatic disease (Dutcher et al., 2020; Hollingsworth et al., 2006).
Advanced RCC patients exhibit progression-free and overall
survival of less than two years in the majority of cases
(Acquavella and Fojo, 2013; Lee-Ying et al., 2014; Rini, 2010).
Therefore, further research is required to identify and develop
more effective mRCC treatment strategies. Given that the lungs are
the most common metastatic site (accounting for up to 60% of
metastases) (Motzer et al., 1996), it is imperative to develop
preclinical models capable of facilitating elucidation of pulmonary
mRCC biological mechanisms and identification of more effective
treatment strategies with superior toxicity profiles. Modern
immunotherapies inhibit programmed cell death protein 1 (PD-1)-,
programmed death-ligand 1 (PD-L1)-, or cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4)-based immune checkpoints. This
ameliorates immune evasion by tumor cells largely without
significant adverse effects (Motzer et al., 2018, 2019; Rini et al.,
2019). Evaluation of such therapies within the present context
requires hosts with intact and functional immune systems. We
therefore developed a murine RCC model based on the well-
described Renca cell line, originally derived from BALB/c mouse
spontaneous renal adenocarcinoma (Salup and Wiltrout, 1986).
While most studies inject Renca cells subcutaneously to produce
easily assessable local tumors, such an approach lacks anatomical
relevance to RCC. In addition, intravenous injection of Renca cells
establishes a pulmonary tumor burden, but does not allow for
observation of migration from the primary to the secondary tumor
site to investigate metastatic pathogenesis. Lack of an appropriate
pulmonary mRCC animal model (i.e. one that mimics the tumor
microenvironment, infiltration into local vasculature, and organ-tumor
cellular communication (Murphy et al., 2017)) contributes to the high
failure rate of novel anticancer drugs in this context (Ocana et al., 2011).
A model simultaneously exhibiting both primary and metastatic
disease would facilitate crucial research examining the progression
of mRCC to identify and evaluate appropriate treatment strategies.
This is particularly relevant when considering that mRCC patients
typically display pulmonary metastases, and that metastases are the
major cause of mortality in these patients. The present study
implants luciferase-expressing Renca cells (Renca/luc) and selects
a highly pulmonary metastatic subset [Renca(HM)/luc] for
reimplantation, thereby establishing a highly efficient and
consistent murine model of pulmonary mRCC that recapitulates
major aspects of human mRCC. This provides a more suitable
model for the in vivo study of this cancer and its treatment.
RESULTS
Briefly, Renca/luc cells were orthotopically implanted into the
kidneys of an initial set of mice via injection. Progression of RCCReceived 9 January 2021; Accepted 25 March 2021
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(including metastasis) was evaluated at intervals via bioluminescent
imaging (BLI). After sacrifice, renal and pulmonary tumor burdens
were evaluated, and Renca(HM)/luc cells were isolated from
pulmonary metastases for reimplantation into a second set of
mice. Tumor progression and organ tumor burdens were again
evaluated. After the mice were euthanized, pulmonary metastatic
cells were again isolated for reimplantation into a third set of mice,
and identical evaluations were repeated a final time. In order to
verify that cells from the kidney tumors and pulmonary metastases
originated from same Renca/luc cells that were injected, we have
checked the morphology of cells from both kidney tumors and
pulmonary metastases that represented to be identical (Fig. S1).
Moreover, we could simultaneously detect BLI signal intensity
from both the kidney and lung fields, supporting that Renca/luc cells
which was implanted to the kidney were metastasized to the lung.
After Renca/luc cell implantation, all mice developed renal tumors
and lung metastases. The in vivo imaging system (IVIS)
longitudinally tracked tumor burden (Fig. 1A). BLI signal intensity
was higher in Renca(HM)/luc cell-implanted mice than in Renca/luc
cell-implanted mice (Fig. 1B). BLI signal intensity was higher in
Renca(HM)/luc-cell-implanted mice (0.24×108±0.07×108 photons/
sec, n=3) than in Renca/luc-cell-implanted mice (0.03×108±
0.01×108 photons/sec, n=3) with significance (P=0.030) on day 5
post implantation. This difference was more pronounced over time
with the BLI signal intensity of 23 post implantation of Renca(HM)/
luc cell-implanted mice (9.81×108±4.45×108 photons/sec, n=12)
higher than in Renca/luc cell-implanted mice (2.22×108±
0.49×108 photons/sec, n=12) with significance (P=0.043). The
post-implantation survival interval was calculated at a mean of
23 days.
Because tumor cell populations are heterogeneous, displaying
differential metastatic capabilities (Fidler and Kripke, 1977), an
in vivo selection approach was used to isolate a highly metastatic
(HM) subpopulation of Renca/luc cells, termed Renca(HM)/luc, with
unique characteristics underlying their preference for pulmonary
metastasis (Fig. 2). After Renca(HM)/luc cell implantation, mice
demonstrated a significant decrease in survival: Renca(HM)/luc cell-
implanted mice were euthanized 18.6±2.9 days post-implantation,
whereas Renca/luc cell-implanted mice were euthanized 22.3±
1.1 days post-implantation (P=0.001, n=10 for each group;
Fig. 3A). To assess the degree of metastatic enhancement induced
by consecutive in vivo selection, Renca(HM)/luc cells were again
isolated and reimplanted into a third set of mice, but no superior
metastatic potential was observed after this second passage.
Specifically, no significant difference in survival was observed
(relative to the original Renca(HM)/luc cell-implanted mice;
P=0.785, n=10 for each group; Fig. 3A). Furthermore, the number
of observed pulmonary metastatic lesions did not differ significantly
between the original Renca(HM)/luc cell-implanted mice (172.6±
38.2) and Renca(HM)/luc cell-reimplanted mice (183.9±39.0;
P=0.521, n=10 for each group).
Original Renca(HM)/luc cell implantation also increased renal
tumor growth rate, resulting in larger tumors and a higher tumor
burden. Renca(HM)/luc cell-implanted mice demonstrated a
significantly higher tumor burden (2.0±1.0 g) than Renca/luc cell-
implanted mice (1.2±0.5 g; P=0.027, n=10 for each group; Fig. 3B).
This difference was observed by day 14 and became more
pronounced over time (Fig. 3C). No difference in weight of the
tumor-bearing kidney was observed by day 5 post implantation
{0.22±0.02 g (Renca/luc, n=3), 0.22±0.01 g [Renca(HM)/luc,
n=3]; P=1.000}, but significant differences were observed on day
Fig. 1. Bioluminescent imaging (BLI) of orthotopically implanted Renca
cells and spontaneous lung metastases. (A) Representative
bioluminescent images of BALB/c mice following intrarenal injection of
1×105 Renca/luc or Renca(HM)/luc cells. (B) Higher BLI signal intensity
(higher tumor burden) on day 5 following Renca(HM)/luc cell implantation
(relative to day 9 following Renca/luc cell implantation) (n=2 for each day 5,
9, 14, 19, and 23 post implantation, total n=10 for Renca/luc and
Renca(HM)/luc, respectively).
Fig. 2. Schematic representation of the in vivo selection process. Cell
lines were intrarenally injected (orthotopic implantation) in mouse (A),
followed by isolation of tumor cells from pulmonary metastases for
expansion culture and reinjection in another mouse (B). (1) Initial Renca/luc
cell implantation. (2) Isolation of metastatic tumor cells from pulmonary
lesions. (3) In vivo selection of the highly pulmonary metastatic cell
subpopulation, termed Renca(HM)/luc. (4) Final reimplantation of
Renca(HM)/luc cells.
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23 post-implantation {1.17±0.33 g (Renca/luc, n=12), 2.33±0.50 g
[Renca(HM)/luc, n=12]; P=0.029}.
Finally, Renca(HM)/luc cell implantation resulted in a shorter
interval to development of pulmonary metastases and increased the
number of lung metastatic lesions (relative to Renca/luc cell
implantation). Pulmonary metastasis was first observed via IVIS in
Renca(HM)/luc-cell-implanted mice 5 days post-implantation, at
which time Renca/luc cell-implanted mice exhibited no pulmonary
metastases (Fig. 4A). Pulmonary metastasis was confirmed by
India ink insufflation (Fig. 4B,C). The number of lung metastases
on day 23 post implantation in Renca(HM)/luc cell-implanted mice
(172.6±38.2) was significantly higher than that in Renca/luc cell-
implanted mice (90.1±22.8; P<0.001, n=10 for each group).
Pulmonary metastases developed more rapidly in Renca(HM)/luc
cell-implanted mice, with a maximum growth rate difference on day
19 post-implantation (Fig. 4D).
DISCUSSION
Despite the existence of multiple mRCC treatment modalities, overall
survival remains low (under 2 years for the majority of patients), and
no consensus has been achieved regarding an optimal treatment
regimen (Czarnecka et al., 2014; Dutcher et al., 2020). Therefore, the
development of more effective mRCC therapeutic interventions is
required, which necessitates translationally relevant pre-clinical
mRCC animal models, especially for pulmonary metastatic disease,
as this is the most common site of RCC metastasis (Motzer et al.,
1996). Therefore, we employed in vivo passage of the Renca cell line
to develop a relevant immunocompetent BALB/c murine RCC
model that efficiently develops pulmonary metastases. This model
recapitulates an important hallmark of advanced human RCC
(development of distant pulmonary metastases originating from a
primary renal tumor) and offers the significant advantage of using a
syngeneic tumor cell line to evaluate tumor progression and
regression in an immunologically intact animal (James et al., 2012,
2014; Norian et al., 2012).
Few mRCC animal models have been developed (Murphy et al.,
2017; Strube et al., 2010), and no other group has reported the
development of a highly efficient pulmonary metastatic model. Since
efficiency is a desirable model characteristic to produce time-efficient
and cost-effective animal experiments, we used in vivo passage to
select a highly metastatic cell subpopulation to overcome the long
implantation-metastasis interval of the parental Renca/luc cell line.
Moreover, an ideal model exhibits minimal variation between mice
with respect to tumor progression. In vivo selection also helps address
the heterogeneity inherent in cancer cell populations, including
differential growth rates and metastatic potentials (Fidler and Kripke,
1977). In the present study, consecutive in vivo selection
[reimplantation of Renca(HM)/luc cells] demonstrated that a single
round of selection is sufficient to produce Renca(HM)/luc cells with
relatively maximal metastatic potential. Thus, in vivo selection has
facilitated the development of a murine model exhibiting a short
implantation-metastasis interval as well as equivalent rates of cancer
development between mice, which is suitable for pre-clinical
therapeutic testing. While two other studies have used the in vivo
selection approach to develop highly bone metastatic RCC models
(Kang et al., 2003; Strube et al., 2010), the present study is the first to
apply this methodology to developing a highly pulmonary metastatic
RCC model.
A luciferase-expressing tumor cell line makes non-invasive
longitudinal tracing and measurement of in vivo tumors feasible,
representing a further advantage over the common orthotopic
implantation model (in which tumor growth cannot be visualized in
real time) as well as the subcutaneous implantation tumor model (in
which tumor growth may only be measured by calipers). In addition,
the subcutaneous tumor model does not exhibit metastasis to distal
organs; the highly pulmonary metastatic model presented herein
facilitates the elucidation of the pathological mechanisms underlying
the metastasis of primary RCC to the lungs. Moreover, the present
study demonstrates clear visualization of early pulmonary metastasis
via BLI. Non-invasive detection of pulmonary metastases would
facilitate determination of ideal treatment initiation times during
experiments.
Numerous efforts to improve the survival of patients with mRCC
have been made, which lead to enhanced survival in this era of
targeted therapies and immunotherapies (Dizman et al., 2020; Tippu
et al., 2020). Currently there exist several target agents of mRCC
including vascular endothelial growth factor (VEGF) tyrosine kinase
inhibitors, anti-VEGFmonoclonal antibodies, and mammalian target
of rapamycin (mTOR) inhibitors (Dizman et al., 2020; Tippu et al.,
2020). Moreover, modern immunotherapies have been recently
developed which target against PD-1, PD-L1, or CTLA-4, which
disable the ability of tumor cells to evade the immune system without
any significant side effects, especially in mRCC (Motzer et al., 2018,
2019; Rini et al., 2019). Therefore, we have focused on increasing the
efficacy of modern immunotherapies in mRCC patients. We are
currently under evaluation of clinical benefit of oncolytic virus which
Fig. 3. Progression rate of primary renal tumors and lung metastatic lesions. (A) Kaplan–Meier survival curves, indicating significantly shorter survival
intervals for Renca(HM)/luc cell-implanted mice than for Renca/luc cell-implanted mice (n=10 for Renca/luc and Renca(HM)/luc). The dotted line represents
the Kaplan–Meier survival curve following final Renca(HM)/luc cell-reimplantation(2nd study, n=10). (B) Excised tumor-bearing kidney weights of Renca/luc
cell-implanted mice relative to those of Renca(HM)/luc cell-implanted mice (n=10 for Renca/luc tumor-bearing, and Renca(HM)/luc tumor bearing kidneys).
(C) Higher weight of the tumor-bearing kidney (more rapid tumor growth) following Renca(HM)/luc cell implantation (relative to Renca/luc cell implantation)
(n=2 for each day 5, 9, 14, 19, and 23 post-implantation, total n=10 for Renca/luc and Renca(HM)/luc, respectively).
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would increase sensitivity to PD-1 and CTLA-4 targeted
immunotherapies, comparing with conventional targeted therapies
including VEGF tyrosine kinase inhibitor and mTOR inhibitor using
the model demonstrated here.
Furthermore, numerous genetic biomarkers have been developed,
however, none of these markers have been clinically used in
practice. Therapeutic and prognostic biomarkers would guide
treatment of mRCC patients in determining the most effective
therapeutic options. Therefore, we are planning on future studies
that focus on unraveling the clinically feasible biomarkers of mRCC
using this model.
There are few limitations of this study. First, due to the
limitation of the number of mice used, only the small number of
mice was used to compare between Renca/luc and Renca(HM)/luc
cell-implanted mice group during the follow-up, euthanizing two
mice per each day 9, 14, 19, and 23 post-implantation and two
mice on day 5 post-implantation. Increasing the number of mice
per each day would increase the total number of mice tenfold.
Therefore, we allocated the minimum number of two mice in each
day except day 5, in order to calculate statistical significance, and
planned re-experiment when there is discrepancy between two
mice. However, there was no discrepancy between two mice in
each day and group. Second, due to the small number of mice in
each group, statistical significance could not be calculated in some
variables.
In conclusion, given the current increase in appreciation for the
utility of anticancer immunotherapy, the need for appropriate
pathophysiologically and clinically relevant animal models has
increased concomitantly. The syngeneic, orthotopic, highly
pulmonary metastatic RCC murine model presented herein is
clinically relevant and highly efficient, exhibiting renal tumors that
spontaneously produce pulmonary micrometastases as early as 5 days
post-implantation. It will facilitate both the elucidation of biological
mechanisms underlying pulmonary metastasis and the evaluation of
multiple mRCC treatment modalities, including targeted therapies and
immunotherapies.
Fig. 4. Spontaneous lung metastasis
following intrarenal implantation of
highly pulmonary metastatic
Renca(HM)/luc cells. (A) Bioluminescent
imaging demonstrating early (day 5) lung
metastatic lesions in Renca(HM)/luc cell-
implanted mice versus no signal in
Renca/luc cell-implanted mice.
(B) Number of pulmonary metastatic
lesions over time, demonstrating more
lesions in Renca(HM)/luc cell-implanted
mice than in Renca/luc cell-implanted
mice. (C) Pulmonary metastatic lesions
visualized via India ink-insufflation in
Renca/luc cell-implanted mice and
Renca(HM)/luc cell-implanted mice on
day 23 post-implantation. Scale bars:
5 mm. (D) Number of pulmonary
metastases over time, demonstrating
significantly more lesions in Renca(HM)/
luc cell-implanted mice than in Renca/luc
cell-implanted mice [n=2 for each day 5,
9, 14, 19, and 23 post-implantation, total
n=10 for Renca/luc and Renca(HM)/luc,
respectively].
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Animal experiments were conducted in accordance with the Guide to the
Care and Use of Laboratory Animals approved by the Association for
Assessment and Accreditation of Laboratory Animal Care and the National
Institutes of Health guidelines. The experimental protocol was approved by
the Institutional Animal Care and Use Committee (IACUC) of Yonsei
University Health System (IACUC No. 2019–0151), following guidelines
specified by the Institute of Laboratory Animal Resources Commission on
Life Sciences National Research Council in the USA.
A total of 52 adult male BALB/c mice (Orient Bio Inc., Seongnam,
GyeongGi-Do, Korea) aged 6–7 weeks, were maintained in clean animal
facilities at Yonsei University Health System. Mice were housed five to a cage,
with ad libitum access to autoclaved food, water, and bedding. Mice were
euthanizedwhen they becamemoribund. Among 52mice, total 30micewith 10
mice in each group [n=10 for Renca/luc, Renca(HM)/luc, and Renca(HM)/luc-
reimplanted, respectively] weremeasured for survival, tumor growth, BLI signal
intensity and number of lung metastasis at the end-of the study which was set as
the time point of 23 days (Fig. S2A). For the measurement by the time points, a
total of 20 mice with ten mice per each group of Renca/luc and Renca(HM)/luc
(Fig. S2B) were used and twomice euthanized for each day 5, 9, 14, 19, and 23
post-implantation to measure BLI signal intensity (Fig. 1B), tumor-bearing
weights (Fig. 3C), and number of lung metastasis (Fig. 4D) to observe the
tendency according to the time not to compare statistical significance.
Cell lines
Initially described in 1973, the Renca cell line was derived from a
spontaneously arising murine renal adenocarcinoma; it is syngeneic in
BALB/c mice and grows unimpeded in such animals (Murphy and
Hrushesky, 1973). Cells were grown in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS; Gibco, Waltham, MA, USA), and 1% penicillin-
streptomycin (Gibco). Cells were incubated in 5% CO2 at 37°C.
To induce stable expression of red fluorescent protein (RFP) and firefly
luciferase (luc), Renca cells were transfected using a commercially available
lentiviral vector containing luc 3 and RFP genes under control of an
inducible suCMV promoter (Amsbio, Cambridge, MA, USA). Luciferase
and RFP were bicistronically expressed as individual proteins from a single
mRNA, mediated by a 2A peptide to ensure equimolar expression of both
proteins. Additionally, a puromycin resistance marker was expressed under
an RSV promoter to facilitate dual selection of successfully transduced cells
via both RFP signal detection and puromycin resistance.
Renca/luc cells were grown to sub-confluence, harvested using 0.25%
trypsin, resuspended in complete RPMI 1640 medium, and centrifuged to
remove the supernatant. A hemocytometer was used to count viable cells,
and volume was adjusted using Hank’s Balanced Salt Solution (HBSS) to
yield a concentration of 2×106 cells/ml. The suspension was aspirated into a
glass syringe coupled to a 22-gauge needle (both Hamilton, Bonaduz, GR,
Switzerland) for orthotopic renal injection (implantation).
Orthotopic implantation
Orthotopic implantation was performed as previously described (Murphy
et al., 2017). Briefly, mice were anesthetized using intraperitoneal instillation
of 30 mg/kg zoletil and 10 mg/kg rompun. A surgical anesthetic plane was
confirmed via the toe-pinch test. The left flankwas shaved and sterilized using
a povidone-iodine solution, a 1 cm vertical incision was made using surgical
scissors, and the dermis was separated from the peritoneum. The spleen and
kidneys were identified through the peritoneum, both visually and by
palpating the mouse from below. A 50 µl aliquot of cell suspension
(corresponding to 1×105 cells) was slowly injected, the needle was held in
place for 5–10 s to minimize cell backflow, and the incision was closed after
the needle was withdrawn. Post-operatively, animals were allowed to recover
in a clean cage equipped with a warming pad.
Serial passage to establish a highly pulmonary metastatic cell
line subpopulation
Threeweeks post-implantation of Renca/luc cells, micewere sacrificed, lungs
were harvested, and pulmonary metastases were precisely harvested with the
assistance of fluorescence microscopy. Pulmonary metastatic lesions were
dissociated to form a single-cell suspension using the gentleMACS™ Tumor
Dissociation Kit (Miltenyi Biotec, Auburn, CA, USA), according to the
manufacturer’s instructions. Tumor cells were purified from this suspension
using a Tumor Cell Isolation Kit (Miltenyi Biotec), according to the
manufacturer’s instructions. This pulmonary metastatic cell subpopulation
was termed Renca(HM)/luc and was maintained in RPMI 1640 medium
supplemented with 10% FBS prior to again being intrarenally implanted,
including subsequent isolation of pulmonary metastases (following an
identical procedure to that described above). After each implantation, the
interval to metastasis, tumor progression, and the interval to moribundity or
demise were monitored.
Bioluminescent imaging
To detect Renca/luc tumor cell dissemination, non-invasive, whole-body
BLI was applied—using a charge-coupled device camera (Roper Scientific,
Inc./Photometrics, Tucson, AZ, USA)—on days 5, 9, 14, 19, and 23 post-
implantation. After anesthesia, mice received intraperitoneal instillations of
luciferin (0.1 ml of a 30 mg/ml solution in sterile phosphate-buffered saline
(PBS)). After 10 min, mice were placed in the BLI system and tumor
burdens were evaluated in terms of photons of light emitted per second
within a defined region of interest.
Organ harvesting and evaluation
Mice exhibiting pulmonary metastatic lesions were sacrificed for organ
harvesting. Prior to excision, the degree of pulmonarymetastasis was assessed
by insufflating the lungs with India ink. After excision and prior to weighing,
extraneous connective tissue was removed from the tumor-bearing kidney,
contralateral kidney, and lungs. Lungs were then immediately fixed in
Fekete’s solution, followed by manual counting of lung surface metastatic
lesions under a dissecting microscope.
Statistical analysis
Survival, tumor-bearing kidney weights, BLI signal intensity and
number of pulmonary metastatic lesion comparisons on day 23 post-
implantation employed n=10 or 12 mice per group, while tumor-bearing
kidney weights, and BLI signal intensity comparisons on day 5 post-
implantation employed n=3 per group. All results are expressed as the
mean±standard deviation (s.d.). Student’s t-test was used to compare
continuous variables, and Fisher’s exact test was used to compare
categorical variables. Kaplan–Meier survival analysis (using the Log-
Rank test) was performed to compare survival probabilities. Statistical
analyses were performed using SPSS version 23.0 (IBM Corp., Armonk,
NY, USA) and GraphPad Prism version 8.0 (GraphPad Software, Inc., La
Jolla, CA, USA). All statistical tests were two-tailed, and P-values <0.05
were considered significant.
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